GPR44 as a Target for Imaging Pancreatic Beta-Cell Mass
1
2
Antaros Medical AB, Mölndal, Sweden
|
Publication type: Journal Article
Publication date: 2019-06-27
scimago Q1
wos Q1
SJR: 2.163
CiteScore: 12.0
Impact factor: 6.4
ISSN: 15344827, 15390829
PubMed ID:
31250117
Endocrinology, Diabetes and Metabolism
Internal Medicine
Abstract
Quantitative markers for beta-cell mass (BCM) in human pancreas are currently lacking. Medical imaging using positron emission tomography (PET) markers for beta-cell restricted targets may provide an accurate and non-invasive measurement of BCM, to assist diagnosis and treatment of metabolic disease. GPR44 was recently discovered as a putative marker for beta cells and this review summarizes the developments so far. Several small molecule binders targeting GPR44 have been radiolabeled for PET imaging and evaluated in vitro and in small and large animal models. 11C-AZ12204657 and 11C-MK-7246 displayed a dose-dependent and GPR44-mediated binding to beta cells both in vitro and in vivo, with negligible uptake in exocrine pancreas. GPR44 represents an attractive target for visualization of BCM. Further progress in radioligand development including clinical testing is expected to clarify the role of GPR44 as a surrogate marker for BCM in humans.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Molecules
2 publications, 13.33%
|
|
|
Frontiers in Endocrinology
2 publications, 13.33%
|
|
|
Nuclear Medicine and Biology
2 publications, 13.33%
|
|
|
Pharmaceuticals
2 publications, 13.33%
|
|
|
Pharmaceutics
1 publication, 6.67%
|
|
|
International Journal of Molecular Sciences
1 publication, 6.67%
|
|
|
Biomedicines
1 publication, 6.67%
|
|
|
International Journal of Radiation Biology
1 publication, 6.67%
|
|
|
Seminars in Cell and Developmental Biology
1 publication, 6.67%
|
|
|
Current Opinion in Endocrine and Metabolic Research
1 publication, 6.67%
|
|
|
Biomolecules
1 publication, 6.67%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
8
|
|
|
MDPI
8 publications, 53.33%
|
|
|
Elsevier
4 publications, 26.67%
|
|
|
Frontiers Media S.A.
2 publications, 13.33%
|
|
|
Taylor & Francis
1 publication, 6.67%
|
|
|
1
2
3
4
5
6
7
8
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
15
Total citations:
15
Citations from 2024:
2
(13.34%)
Cite this
GOST |
RIS |
BibTex
Cite this
RIS
Copy
TY - JOUR
DO - 10.1007/s11892-019-1164-z
UR - https://doi.org/10.1007/s11892-019-1164-z
TI - GPR44 as a Target for Imaging Pancreatic Beta-Cell Mass
T2 - Current Diabetes Reports
AU - Eriksson, Olof
PY - 2019
DA - 2019/06/27
PB - Springer Nature
IS - 8
VL - 19
PMID - 31250117
SN - 1534-4827
SN - 1539-0829
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Eriksson,
author = {Olof Eriksson},
title = {GPR44 as a Target for Imaging Pancreatic Beta-Cell Mass},
journal = {Current Diabetes Reports},
year = {2019},
volume = {19},
publisher = {Springer Nature},
month = {jun},
url = {https://doi.org/10.1007/s11892-019-1164-z},
number = {8},
pages = {49},
doi = {10.1007/s11892-019-1164-z}
}